Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

Metabolic disturbances and defects in insulin secretion in rats with streptozotocin-nicotinamide-induced diabetes.

Szkudelski T, Zywert A, Szkudelska K.

Physiol Res. 2013;62(6):663-70. Epub 2013 Jul 17.

3.

Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model.

Szkudelski T.

Exp Biol Med (Maywood). 2012 May;237(5):481-90. doi: 10.1258/ebm.2012.011372. Epub 2012 May 22. Review.

PMID:
22619373
4.

Diabetic characteristics and alveolar bone loss in streptozotocin- and streptozotocin-nicotinamide-treated rats with periodontitis.

Kim JH, Lee DE, Choi SH, Cha JH, Bak EJ, Yoo YJ.

J Periodontal Res. 2014 Dec;49(6):792-800. doi: 10.1111/jre.12165. Epub 2014 Feb 3.

PMID:
24490978
5.

Glucagon, insulin and somatostatin secretion in response to sympathetic neural activation in streptozotocin-induced diabetic rats. A study with the isolated perfused rat pancreas in vitro.

Kurose T, Tsuda K, Ishida H, Tsuji K, Okamoto Y, Tsuura Y, Kato S, Usami M, Imura H, Seino Y.

Diabetologia. 1992 Nov;35(11):1035-41.

PMID:
1361917
6.

Adipocyte dysfunction in rats with streptozotocin-nicotinamide-induced diabetes.

Szkudelska K, Nogowski L, Szkudelski T.

Int J Exp Pathol. 2014 Apr;95(2):86-94. doi: 10.1111/iep.12073.

8.

CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.

Sunil V, Verma MK, Oommen AM, Sadasivuni M, Singh J, Vijayraghav DN, Chandravanshi B, Shetty J, Biswas S, Dandu A, Moolemath Y, Venkataranganna MV, Somesh BP, Jagannath MR.

BMC Pharmacol Toxicol. 2014 Mar 25;15:19. doi: 10.1186/2050-6511-15-19.

10.
11.
12.

[Establishment and application of the model of islet impaired by NO free radical released from streptozotocin].

Qian FY, Ouyang F, Fu DX, Ren TR.

Sheng Wu Gong Cheng Xue Bao. 2003 May;19(3):349-52. Chinese.

PMID:
15969020
13.

Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide.

Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G.

Diabetes. 1998 Feb;47(2):224-9.

PMID:
9519717
14.
15.

Protective effect of gamma-hydroxybutyrate and nicotinamide on low-dose streptozotocin-induced diabetes in mice.

Bouix O, Reynier M, Guintrand-Hugret R, Orsetti A.

Horm Metab Res. 1995 May;27(5):216-20.

PMID:
7642171
16.

Glucose and ATP levels in pancreatic islet tissue of normal and diabetic rats.

Matschinsky FM, Pagliara AS, Stillings SN, Hover BA.

J Clin Invest. 1976 Nov;58(5):1193-200.

17.

Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes.

Akarte AS, Srinivasan BP, Gandhi S.

J Diabetes Complications. 2012 Jul-Aug;26(4):266-74. doi: 10.1016/j.jdiacomp.2012.03.013. Epub 2012 May 22.

PMID:
22626875
18.

cAMP-secretion coupling is impaired in diabetic GK/Par rat β-cells: a defect counteracted by GLP-1.

Dolz M, Movassat J, Bailbé D, Le Stunff H, Giroix MH, Fradet M, Kergoat M, Portha B.

Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E797-806. doi: 10.1152/ajpendo.00652.2010. Epub 2011 Jul 12.

19.

Beta-cell function and mass in type 2 diabetes.

Larsen MO.

Dan Med Bull. 2009 Aug;56(3):153-64.

PMID:
19728971
20.

Supplemental Content

Support Center